TOKYO, Mar 31 (Pulse News Wire) – GNI Group Ltd. (2160.T) disclosed its revenue forecast for the fiscal year ending December 31, 2026, despite uncertainties surrounding regulatory approvals and investment timelines.
The company expects sales revenue of approximately ¥16.00 billion for the upcoming fiscal year, down from previous estimates due to ongoing regulatory hurdles and strategic investments yet to be finalized. In a statement, CEO In Ruohao noted that while existing operations are relatively stable, significant portions of future earnings remain contingent upon regulatory permissions for new pharmaceutical products and expansion plans in medtech. Specifically, the launch timing of new drugs and the rollout of private brand initiatives in the United States and Asia are subject to approval processes which cannot be accurately predicted at this stage.
The company also highlighted challenges in forecasting operating profits and net income due to unpredictable factors such as research and development costs, pre-investment activities tied to pending drug approvals, and potential debt relief benefits from recent acquisitions. As a result, GNI Group decided to withhold detailed profit projections until further clarity emerges. GNI Group's revenue forecasts for past fiscal years show a trend of increasing sales, with revenues reaching ¥26.84 billion in fiscal 2025.
However, the firm’s outlook for the current fiscal year reflects cautious optimism amid evolving market conditions and regulatory landscapes.
🟢 Confidence: High AI-translated content.